The Glycemia Risk Index (GRI) as a Biomarker for Subclinical Endothelial Dysfunction in Type 1 Diabetes: A Cross-Sectional Study

血糖风险指数(GRI)作为1型糖尿病亚临床内皮功能障碍的生物标志物:一项横断面研究

阅读:2
作者:Nicole Di Martino,Silvia Angelino ,Antonietta Maio,Paolo Cirillo,Alessandro Pontillo,Mariangela Caputo,Lorenzo Scappaticcio,Paola Caruso,Miriam Longo,Giuseppe Bellastella,Maria Ida Maiorino,Katherine Esposito

Abstract

Circulating levels of endothelial progenitor cells (EPCs) involved in endothelial homeostasis are often reduced in people with type 1 diabetes (T1D). The Glycemia Risk Index (GRI) quantifies the quality of glucose control by assessing both hypo- and hyperglycemia risk. We aim to investigate the association between the GRI and circulating EPC levels in people with T1D. This cross-sectional study included 132 adults with T1D, on intensive insulin therapy. We calculated GRI from 14 days continuous glucose monitoring-derived metrics and quantified EPCs count by flow cytometry, stratifying results by GRI zones, ranging from A (lowest risk) to E (highest risk). Higher GRI scores were significantly associated with poorer metabolic parameters. Circulating levels of CD34+, CD133+, KDR+, and CD34+KDR+ cells were lower in participants with a worse GRI compared to adults with a better GRI. Linear regression analyses showed a negative association between GRI and CD34+ (β = -1.079, p = 0.006), CD34+CD133+ (β = -0.581, p = 0.008), and CD34+KDR+ (β = -0.147, p = 0.010). No significant association was found between HbA1c and any EPC phenotype. Adults with T1D and a high GRI level had a lower EPCs count. GRI was significantly associated with certain EPC phenotypes, suggesting its potential role as a biomarker for cardiovascular risk assessment.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。